|Updates from the National Cancer Institute|
|Clinical Trials News|
|Meeting Patients Where They Are: Liberating Clinical Trials Data Under the Cancer Moonshot|
NCI is redesigning the way patients and oncologists find information and learn about cancer clinical trials by making NCI-supported trials available through an application programming interface (API).
|Send Us Your Feedback|
Do you have ideas on how NCI can improve clinical trials search? Visit the feedback form on our clinical trials search page to tell us about them.
|Clinical Trials Information for Patients and Caregivers|
|Phases of Clinical Trials|
Clinical trials to test new cancer treatments involve a series of steps, called phases. Learn about the different clinical trial phases, the purpose of each phase, and the number of people who take part.
|Randomization and Bias in Cancer Clinical Trials|
Randomization, in which people are assigned to groups by chance alone, helps prevent bias in research. Learn more about bias and how randomization works in clinical trials.
|Featured NCI-Supported Clinical Trials|
|Methoxyamine and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas|
This phase l/ll study is for patients with solid tumors or lymphomas that have come back after a period of improvement. Methoxyamine and temozolomide work in different ways to stop the growth of tumor cells. Methoxyamine may also increase the effectiveness of temozolomide against tumor cells. Giving them together may kill more tumor cells.
|Selumetinib and Cyclosporine for Patients with Advanced or Metastatic Colorectal Cancer or Other Advanced Solid Tumors|
This phase l trial is for patients who have solid tumors, including colorectal cancer, that has spread. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cyclosporine may stimulate or suppress the immune system and stop tumor cells from growing. Giving selumetinib and cyclosporine may be a better treatment for colorectal cancer or other solid tumors.
|Glembatumumab Vedotin for Patients with Uveal Melanoma|
This phase II trial is for patients with uveal melanoma that spread to other parts of the body or has returned near the same place. Glembatumumab vedotin may shrink the tumor by binding to tumor cells and delivering tumor-killing substances to them.
Alzheimer's Research & Therapy | Home page
Hace 2 horas